{
    "nct_id": "NCT04692831",
    "official_title": "Imaging of HER2-expressing Cancer With Site-Specifically Labeled 89Zr-ss-Pertuzumab",
    "inclusion_criteria": "* Biopsy proven HER2-positive or HER2-low primary malignancy or metastatic disease\n\nNote: HER2 positivity is defined according to American Society of Clinical Oncology guidelines or ERBB2 amplification on next generation sequencing Note: HER2-low is defined as low HER2 expression, with immunohistochemistry (IHC) 1+ or IHC 2+ and in situ hybridization [ISH]-negative, including FISH.\n\n* Biopsy proven primary malignancy or metastatic disease\n* At least one malignant lesion on CT, MR, or FDG PET/CT within 60 days of protocol enrollment\n* Age 18 years or greater\n* ECOG performance of 0-2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Creatinine > 2 times normal limit (obtained with 8 weeks of enrollment)\n* AST/ALT > 2 times normal limit (obtained with 8 weeks of enrollment)\n* Life expectancy < 3 months\n* Pregnancy or lactation\n* Patients who cannot undergo PET/CT due to weight limits (over 450 pounds)",
    "miscellaneous_criteria": ""
}